Dedes et al. reported that KU0058948, a first generation PARP-inhibitor, had higher efficiency in PTEN-deficient endometrial cells than in wild-type PTEN endometrial carcinoma cell lines [29]. This evidence concerns the gene PARP1 and endometrial carcinoma.